keyword
https://read.qxmd.com/read/38628626/effects-of-abrocitinib-on-pruritus-and-eczema-symptoms-and-tolerance-in-patients-with-moderate%C3%A2-to%C3%A2-severe-atopic-dermatitis-in-randomized-double%C3%A2-blind-and-placebo%C3%A2-controlled-trials-a-systematic-review-and-a-meta%C3%A2-analysis
#21
JOURNAL ARTICLE
Xingxing Xie, Jie Zhang, Fujing Huang, Ling Fan
Abrocitinib is a highly selective Janus kinase 1 (JAK1) inhibitor that can block a multitude of inflammatory signaling pathways that underlie atopic dermatitis (AD). In addition, abrocitinib inhibits JAK1 signaling in sensory neurons to alleviate acute and chronic pruritus during AD. However, substantial variations in efficacy and safety risks remain due to variations in doses applied in clinical use. Therefore for the present study, differences in the efficacy and tolerability of 100 and 200 mg abrocitinib for treating pruritus and eczema symptoms in patients with moderate-to-severe AD were evaluated compared with placebo...
May 2024: Biomedical Reports
https://read.qxmd.com/read/38628220/modulation-of-the-gut-microbiome-and-firmicutes-phylum-reduction-by-a-nutraceutical-blend-in-the-obesity-mouse-model-and-overweight-humans-a-double-blind-clinical-trial
#22
JOURNAL ARTICLE
Victor Nehmi-Filho, Jessica Alves de Freitas, Lucas Augusto Franco, Roberta Cristina Martins, José Antônio Orellana Turri, Aline Boveto Santamarina, Joyce Vanessa da Silva Fonseca, Ester Cerdeira Sabino, Bruna Carvalho Moraes, Erica Souza, Gilson Masahiro Murata, Silvia Figueiredo Costa, Paulo Sérgio Alcântara, José Pinhata Otoch, Ana Flávia Marçal Pessoa
Overweight and obesity are closely linked to gut dysbiosis/dysmetabolism and disrupted De-Ritis ratio [aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio], which may contribute to chronic noncommunicable diseases onset. Concurrently, extensive research explores nutraceuticals, and health-enhancing supplements, for disease prevention or treatment. Thus, sedentary overweight volunteers were double-blind randomized into two groups: Novel Nutraceutical_(S) (without silymarin) and Novel Nutraceutical (with silymarin)...
April 2024: Food Science & Nutrition
https://read.qxmd.com/read/38628176/safety-assessment-of-a-proprietary-fermented-soybean-solution-symbiota%C3%A2-as-an-ingredient-for-use-in-foods-and-dietary-supplements-non-clinical-studies-and-a-randomized-trial
#23
JOURNAL ARTICLE
Chien-Min Hung, Wen-Cheng Chu, Wen-Yen Huang, Pei-Jung Lee, Wen-Chih Kuo, Cheng-Yu Hou, Chia-Chun Yang, Ai-Jen Yang, Wei-Kai Wu, Ming-Liang Kuo, Ming-Shiang Wu, Wan-Jiun Chen
A safety evaluation was performed of Symbiota®, which is made by a proprietary anaerobic fermentation process of soybean with multistrains of probiotics and a yeast. The battery of genotoxicity studies showed that Symbiota® has no genotoxic effects. Safety and tolerability were further assessed by acute or repeated dose 28- and 90-day rodent studies, and no alterations in clinical observations, ophthalmological examination, blood chemistry, urinalysis, or hematology were observed between the control group and the different dosing groups (1...
April 2024: Food Science & Nutrition
https://read.qxmd.com/read/38628109/withania-somnifera-and-trigonella-foenum-graecum-as-ingredients-of-testosterone-boosting-supplements-possible-clinical-implications
#24
REVIEW
Monika Skrzypiec-Spring, Andrzej Pokrywka, Justyna Kuliczkowska-Płaksej, Adam Szeląg, Marek Bolanowski
This narrative review provides an overview of scientific studies on dietary supplements that may affect circulating testosterone (T) levels to explore which substances are scientifically proven to increase T concentration. We also review the scientific literature for their potential mechanisms and laboratory test changes triggered by their use. Based on the analysis of existing data on substances used to increase endogenous T levels, especially double-blind placebo-controlled randomized clinical trials, we selected 2 herbal extracts with the best documented positive effects on T levels, Withania somnifera root and root extracts/leaves and seed extracts of Trigonella foenum-graecum...
April 17, 2024: Advances in Clinical and Experimental Medicine: Official Organ Wroclaw Medical University
https://read.qxmd.com/read/38627722/evaluation-of-the-effects-of-artemisia-annua-l-and-moringa-oleifera-lam-on-cd4-count-and-viral-load-among-plwh-on-art-at-mbarara-regional-referral-hospital-a-double-blind-randomized-controlled-clinical-trial
#25
JOURNAL ARTICLE
Silvano S Twinomujuni, Esther C Atukunda, Jackson K Mukonzo, Musinguzi Nicholas, Felicitas Roelofsen, Patrick E Ogwang
BACKGROUND: Initiation of ART among people living with HIV (PLWH) having a CD4 count ≤ 350cells/µl, produces poor immunological recovery, putting them at a high risk of opportunistic infections. To mitigate this, PLWH on ART in Uganda frequently use herbal remedies like Artemisia annua and Moringa oleifera, but their clinical benefits and potential antiretroviral (ARV) interactions remain unknown. This study examined the impact of A. annua and M. oleifera on CD4 count, viral load, and potential ARV interactions among PLWH on ART at an HIV clinic in Uganda...
April 16, 2024: AIDS Research and Therapy
https://read.qxmd.com/read/38627638/rimegepant-orally-disintegrating-tablet-75%C3%A2-mg-for-acute-treatment-of-migraine-in-adults-from-china-a-subgroup-analysis-of-a-double-blind-randomized-placebo-controlled-phase-3-clinical-trial
#26
RANDOMIZED CONTROLLED TRIAL
Shengyuan Yu, Aihong Guo, Zhen Wang, Jianguang Liu, Ge Tan, Qian Yang, Mingjie Zhang, Hasiyeti Yibulaiyin, Huisheng Chen, Yongbo Zhang, Robert Croop, Yanhui Sun, Yu Liu, Qian Zhao, Zhihong Lu
BACKGROUND: Rimegepant orally disintegrating tablet (ODT), an oral small-molecule calcitonin gene-related peptide receptor antagonist, is indicated for acute and preventive treatment of migraine in the United States and other countries. Previously, a large clinical trial assessed the efficacy and safety of rimegepant ODT 75 mg for the acute treatment of migraine in adults living in China or South Korea. A post hoc subgroup analysis of this trial was performed to evaluate the efficacy and safety of rimegepant for acute treatment of migraine in adults living in China...
April 16, 2024: Journal of Headache and Pain
https://read.qxmd.com/read/38627070/current-understanding-on-psilocybin-for-major-depressive-disorder-a-review-focusing-on-clinical-trials
#27
REVIEW
Sheng-Min Wang, Sunghwan Kim, Won-Seok Choi, Hyun Kook Lim, Young Sup Woo, Chi-Un Pae, Won-Myong Bahk
Previous studies suggested effectiveness of psilocybin in the field of mental health. FDA designated psilocybin as a "breakthrough therapy" for the treatment of treatment-resistant depression (TRD) in 2018. This paper provided a review of psilocybin's potential role in treatment of depression by focusing on published clinical trials. Studies showed that psilocybin, an agonist on 5-HT2A receptors, manifests antidepressant and anxiolytic effects by increasing glutamate transmission, reducing brain inflammation, decreasing default mode network activity...
May 31, 2024: Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology
https://read.qxmd.com/read/38627035/engot-en20-gog-3083-xport-ec-042-a-phase-iii-randomized-placebo-controlled-double-blind-multicenter-trial-of-selinexor-in-maintenance-therapy-after-systemic-therapy-for-patients-with-p53-wild-type-advanced-or-recurrent-endometrial-carcinoma-rationale-methods
#28
JOURNAL ARTICLE
Ignace Vergote, Alejandro Perez Fidalgo, Giorgio Valabrega, Bradley J Monk, Thomas Herzog, David Cibula, Nicoletta Colombo, Bhavana Pothuri, Jalid Sehouli, Jacob Korach, Joyce Barlin, Christos A Papadimitriou, Toon van Gorp, Debra Richardson, Michael McCarthy, Yoland Antill, Mansoor Raza Mirza, Kai Li, Pratheek Kalyanapu, Brian Slomovitz, Robert L Coleman
BACKGROUND: Patients with advanced/recurrent endometrial cancer have a poor prognosis and limited treatment options. Biomarkers such as tumor protein 53 ( TP53 ) in endometrial cancer can integrate novel strategies for improved and individualized treatment that could impact patient outcomes. In an exploratory analysis of the phase III ENGOT-EN5/GOG-3055/SIENDO study of selinexor maintenance monotherapy 80 mg in advanced/recurrent endometrial cancer, a pre-specified subgroup of patients with TP53 wild type (wt) endometrial cancer showed preliminary activity at long-term follow-up with a generally manageable safety profile (median progression-free survival 27...
April 16, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38626661/a-randomized-double-blind-placebo-controlled-trial-evaluating-the-effect-of-topical-urea-for-secondary-prophylaxis-of-hand-foot-skin-reaction-in-renal-cell-cancer-patients-on-sunitinib-therapy
#29
JOURNAL ARTICLE
Syed Shariq Naeem, Pooja Gupta, Ranjit Kumar Sahoo, V L Kumar, T Velpandian, Archana Singh, Atul Batra, Raja Pramanik, Sameer Rastogi, Saumya Srivastava
INTRODUCTION: Hand foot skin reaction (HFSR) is a common dose-limiting adverse effect of multi kinase inhibitors (MKI) whose mechanism is not fully understood, and the prophylaxis is inadequate. OBJECTIVE: In this pilot study, a double-blind, randomized placebo-controlled trial was conducted to evaluate the effect of topical urea in secondary prevention of sunitinib-induced HFSR in renal cell cancer patients. METHODS: Out of 55 screened patients, 14 were randomized to receive topical urea or placebo for four weeks...
March 13, 2024: Clinical Genitourinary Cancer
https://read.qxmd.com/read/38625730/clinical-efficacy-and-safety-of-intravenous-ferric-carboxymaltose-for-treatment-of-restless-legs-syndrome-a-multicenter-randomized-placebo-controlled-clinical-trial
#30
JOURNAL ARTICLE
Christopher J Earley, Diego García-Borreguero, Mark Falone, John W Winkelman
STUDY OBJECTIVES: Iron therapy is associated with improvements in restless legs syndrome (RLS). This multicenter, randomized, double-blind study evaluated the effect of intravenous ferric carboxymaltose (FCM) on RLS. METHODS: A total of 209 adult patients with a baseline International Restless Legs Syndrome (IRLS) score ≥15 were randomized (1:1) to FCM (750 mg/15 mL) or placebo on study Days 0 and 5. Ongoing RLS medication was tapered starting on Day 5, with the goal of discontinuing treatment or achieving the lowest effective dose...
April 16, 2024: Sleep
https://read.qxmd.com/read/38622543/home-vision-therapy-and-prism-prescription-in-presbyopic-persons-with-convergence-insufficiency-study-protocol-for-a-randomized-controlled-trial
#31
JOURNAL ARTICLE
Saeid Abdi, Haleh Kangari, Saeed Rahmani, Alireza Akbarzadeh Baghban, Zahra Kamary Rad
BACKGROUND: Convergence insufficiency is a common issue in the field of binocular vision. Various treatment options have been suggested for managing this condition, but their efficacy in individuals with presbyopia remains unclear. The objective of this study is to compare the effectiveness of home-based vision therapy and prism prescription, in presbyopic patients with convergence insufficiency. METHODS/DESIGN: It is a randomized, prospective, double-blind clinical trial, with total of 150 participants randomly assigned to the three groups...
April 15, 2024: BMC Ophthalmology
https://read.qxmd.com/read/38622150/lsd-increases-sleep-duration-the-night-after-microdosing
#32
JOURNAL ARTICLE
Nathan Allen, Aron Jeremiah, Robin Murphy, Rachael Sumner, Anna Forsyth, Nicholas Hoeh, David B Menkes, William Evans, Suresh Muthukumaraswamy, Frederick Sundram, Partha Roop
Microdosing psychedelic drugs at a level below the threshold to induce hallucinations is an increasingly common lifestyle practice. However, the effects of microdosing on sleep have not been previously reported. Here, we report results from a Phase 1 randomized controlled trial in which 80 healthy adult male volunteers received a 6-week course of either LSD (10 µg) or placebo with doses self-administered every third day. Participants used a commercially available sleep/activity tracker for the duration of the trial...
April 15, 2024: Translational Psychiatry
https://read.qxmd.com/read/38621497/efficacy-and-safety-of-once-daily-carvedilol-in-atrial-fibrillation-patients-a-randomized-double-blind-placebo-controlled-trial
#33
JOURNAL ARTICLE
Jong-Il Choi, Yae Min Park, Yong-Seog Oh, Jin-Bae Kim, Seongwook Han, Jong-Sung Park, Young Keun On, Kee-Joon Choi, Gyo-Seung Hwang, Moon-Hyoung Lee, Dong-Gu Shin, Nam-Ho Kim, Dae-Kyeong Kim, June Namgung, Dae-Hyeok Kim, Hyung-Wook Park, Hwan-Cheol Park, Eue-Keun Choi, Kyoung Suk Rhee, Seung Yong Shin, Young-Hoon Kim
No abstract text is available yet for this article.
April 13, 2024: Heart Rhythm: the Official Journal of the Heart Rhythm Society
https://read.qxmd.com/read/38619037/teriflunomide-in-pediatric-patients-with-relapsing-multiple-sclerosis-open-label-extension-of-terikids
#34
JOURNAL ARTICLE
Tanuja Chitnis, Brenda Banwell, Ludwig Kappos, Douglas L Arnold, Kivilcim Gücüyener, Kumaran Deiva, Stephane Saubadu, Wenruo Hu, Myriam Benamor, Annaig Le-Halpere, Philippe Truffinet, Marc Tardieu
BACKGROUND: The double-blind TERIKIDS study demonstrated the efficacy and safety of teriflunomide. OBJECTIVE: To evaluate the efficacy, safety, and tolerability of continuous teriflunomide treatment in the TERIKIDS open-label extension. METHODS: In the double-blind period, children with relapsing MS were randomized to placebo or teriflunomide (14 mg adult-equivalent dose) for ⩽ 96 weeks. Participants received teriflunomide for ⩽ 192 weeks post-randomization in the open-label extension...
April 15, 2024: Multiple Sclerosis: Clinical and Laboratory Research
https://read.qxmd.com/read/38618970/combination-of-retagliptin-and-henagliflozin-as-add-on-therapy-to-metformin-in-patients-with-type-2-diabetes-inadequately-controlled-with-metformin-a-multicentre-randomized-double-blind-active-controlled-phase-3-trial
#35
JOURNAL ARTICLE
Yao Wang, Chengxia Jiang, Xiaolin Dong, Mingwei Chen, Qin Gu, Lihui Zhang, Yanqin Fu, Tianrong Pan, Yan Bi, Weihong Song, Jing Xu, WeiPing Lu, Xiaodong Sun, Zi Ye, Danli Zhang, Liang Peng, Xiang Lin, Wei Dai, Quanren Wang, Wenying Yang
AIM: This study assessed the efficacy and safety of co-administering retagliptin and henagliflozin versus individual agents at corresponding doses in patients with type 2 diabetes mellitus who were inadequately controlled with metformin. METHODS: This multicentre, phase 3 trial consisted of a 24-week, randomized, double-blind, active-controlled period. Patients with glycated haemoglobin (HbA1c) levels between 7.5% and 10.5% were randomized to receive once-daily retagliptin 100 mg (R100; n = 155), henagliflozin 5 mg (H5; n = 156), henagliflozin 10 mg (H10; n = 156), co-administered R100/H5 (n = 155), or R100/H10 (n = 156)...
April 15, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38618759/supramolecular-salicylic-acid-combined-with-niacinamide-in-chloasma-a-randomized-controlled-trial
#36
JOURNAL ARTICLE
Ying Xiong, Xian Jiang, Wei Lai, Xinghua Gao, Yan You, Yongmei Huang, Xueli Li, Junling Zhang, Shiqin Tao, Jin Chen, Wei Zhang, Nan Yu, Nan Xu, Chunling Liu, Weihui Zeng, Shichao Lv, Gang Wang
BACKGROUND: No trial of supramolecular salicylic acid (SSA) for chloasma is available yet. OBJECTIVE: The purpose of this study was to assess the efficacy and safety of Bole DA 30% supramolecular salicylic acid (SSA) combined with 10% niacinamide in treating chloasma. METHODS: This multicenter (n=15), randomized, double-blind, parallel placebo-controlled trial randomized the subjects (1:1) to Bole DA 30% SSA or placebo. The primary endpoint was the effective rate after 16 weeks using the modified melasma area severity index (mMASI) [(pretreatment-posttreatment)/pretreatment×100%]...
April 15, 2024: Clinical and Experimental Dermatology
https://read.qxmd.com/read/38618713/predicting-progression-of-intracranial-hemorrhage-in-the-prehospital-txa-for-tbi-trial
#37
JOURNAL ARTICLE
H E Hinson, Hannah Radabaugh, Nincheng Li, Toshinori Fukuda, Jeffrey M Pollock, Martin Schreiber, Susan Rowell, Adam R Ferguson
Progression of intracranial hemorrhage is a common, potentially devastating complication after moderate/severe traumatic brain injury (TBI). Clinicians have few tools to predict which patients with traumatic intracranial hemorrhage on their initial head computed tomographic scan (hCT) scan will progress. The objective of this investigation was to identify clinical, imaging, and/or protein biomarkers associated with progression of intracranial hemorrhage (PICH) after moderate/severe TBI and to create an accurate predictive model of PICH based on clinical features available at presentation...
April 15, 2024: Journal of Neurotrauma
https://read.qxmd.com/read/38618605/use-of-k-y-jelly-on-throat-packs-for-postoperative-sore-throat-after-nasal-surgery-a-randomized-controlled-trial
#38
JOURNAL ARTICLE
Ahmed Mahmoud M M Elgarhy, Saeed Mostafa Abdelhameed, Othman Saadeldien Yahia, Wael Mohamed Elmahdy Ibrahim, Tamer Mohamed Ahmed Ewieda, Mahmoud M Elsayed, Marwa M Abdel-Aziz, Naglaa A Elshehawy, Hussein Magdy Abdelkader, Mahmoud Hamdy Al Boghdady, Ayman Yehia Abbas
Introduction  Postoperative sore throat (POST) is a fairly common side effect of general anesthesia. The K-Y jelly is a well-known lubricant used in many medical procedures. Objective  In this randomized study, we evaluated the use of throat packs soaked with K-Y jelly for POST outcomes in patients submitted to nasal surgery. Methods  The present double-blinded, randomized, controlled study included 140 ASA I-II patients undergoing nasal surgery under general anesthesia. Patients received either or K-Y jelly or water-soaked X-ray detectable throat packs fully inserted into the mouth to occlude the oropharynx...
April 2024: International Archives of Otorhinolaryngology
https://read.qxmd.com/read/38618342/total-knee-arthroplasty-with-and-without-schedule-ii-opioids-a-randomized-double-blinded-placebo-controlled-trial
#39
JOURNAL ARTICLE
Porter F Young, Christopher Roberts, Glenn G Shi, Michael G Heckman, Launia White, Steven Clendenen, Benjamin Wilke
INTRODUCTION: Orthopedic surgeons are the third highest prescribers of narcotics. Previous work demonstrated that surgeons prescribe three times the narcotics required, and most patients do not properly dispose of leftover medication following surgery. This has prompted the creation of multimodal pain regimens to reduce reliance on narcotics. It is unknown if these pathways can effectively eliminate opioids following total knee arthroplasty (TKA). Our purpose was to evaluate a multimodal regimen without schedule II narcotics following TKA, in a randomized, blinded fashion...
March 2024: Curēus
https://read.qxmd.com/read/38617784/perioperative-intravenous-lidocaine-in-thoracoscopic-surgery-for-improved-postoperative-pain-control-a-randomized-placebo-controlled-double-blind-superiority-trial
#40
JOURNAL ARTICLE
Aljaz Hojski, Daniel Bolliger, Makhmudbek Mallaev, Sandrine Dackam, Nikolay Tsvetkov, Mark Wiese, Tobias Schneider, Andreas Lampart, Didier Lardinois
BACKGROUND: Pain, including associated pain management, remains a burden on patients after thoracic surgery. Our objective was to investigate whether perioperative intravenous administration of lidocaine reduces postoperative morphine consumption and pain intensity after video-assisted thoracoscopic surgery (VATS). METHODS: In this double-blind, placebo-controlled superiority trial, patients undergoing VATS with a planned duration of ≤90 minutes were randomized within an intention-to-treat setting...
March 29, 2024: Journal of Thoracic Disease
keyword
keyword
63876
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.